CD19 and B-cell non-Hodgkin lymphoma: A single-center retrospective cohort study including 280 CD19 CAR-T recipients with B cell lymphoma reported a cumulative incidence of 1.07% (3/280) with prophylaxis in a median follow-up of 259 days; other studies with smaller sample sizes identified cumulative incidences range from 1.67% to 7.32% [6, 7, 11].